Public Market Listing
2105HKEX
Live quotes, historical charts, and market capitalization for Laekna Limited are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | AKT (inhibitor)Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 2 | Activin receptor type IIA (ActRIIA)Monoclonal antibody | Obesity | |
| Phase 1 | Activin receptor type IIB (ActRIIB)Monoclonal antibody | Obesity |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
CN, NMPA · Laekna · Source ↗
15 April 2026Topline resultAfuresertibAFFIRM-205 Phase 3 (NCT04851613) met its primary endpoint of PFS
Laekna · Source ↗
Financial reports
Quarterly & interim (3)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-H1 | $22M | $14M | $139M+ $27M short-term inv. | $0.2M | report ↗ |
View 2 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | — | — | $104M | — | report ↗ |
| 2024-H1 | — | — | $89M | — | report ↗ |
Annual history (2 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $15M | $35M | $177M+ $2.7M short-term inv. | $8.0M | report ↗ |
View 1 more year
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | — | $110M | — | report ↗ |